As of September 30, 2023, the Company held cash and cash equivalents and investment securities of $658.9 million, compared to $392.8 million as of December 31, 2022. The Company entered into a royalty agreement in May 2023 and received an upfront payment of $375.0 million, and collected $100.0 million in July 2023 for a milestone due from CSL following the first sale of HEMGENIX in the U.S.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on QURE:
- uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- uniQure N.V. (QURE) Q3 Earnings Cheat Sheet
- uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
- uniQure to resume trading at 7:35 am ET
- uniQure to discontinue over half of research projects, reduce workforce by 20%
